# A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05253651/  
OnCo record `nct05253651` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tucatinib, Trastuzumab, Bevacizumab, Cetuximab and Oxaliplatin in colorectal cancer, run by Seagen, a wholly owned subsidiary of Pfizer, now recruiting.

## Summary

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05253651 by Seagen, a wholly owned subsidiary of Pfizer, with 400 participants planned, started 2022-10-24 and due to reach its primary completion in 2027-12-31. Interventions recorded: tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin and leucovorin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05253651
- Phase: 3
- Setting: An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT05253651: https://clinicaltrials.gov/study/NCT05253651

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Tucatinib](https://onco.cc/drugs/tucatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05253651.json